Tafamidis Accord
Authorised
This medicine is authorised for use in the European Union
tafamidis
MedicineHumanAuthorised
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
Tafamidis Accord is a medicine used to treat hereditary transthyretin amyloidosis, a disease in which abnormal protein fibres called amyloid build up in tissues around the body. It is used in adults with hereditary transthyretin amyloidosis with cardiomyopathy (ATTRh-CM), where amyloid builds up in the heart.
Tafamidis Accord contains the active substance tafamidis and is a ‘generic medicine’. This means that Tafamidis Accord contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU. The reference medicine for Tafamidis Accord is Vyndaqel.
Treatment with Tafamidis Accord should be started and supervised by a doctor knowledgeable in the management of patients with transthyretin amyloidosis or heart muscle disease. It is available as capsules to be taken by mouth once a day.
The medicine can only be obtained with a prescription. For more information about using Tafamidis Accord, see the package leaflet or contact your doctor or pharmacist.
In patients with transthyretin amyloidosis, a blood protein called transthyretin is defective and breaks easily. The broken protein forms a fibrous substance called amyloid that builds up in tissues and organs around the body, including the heart, where it interferes with their normal functions.
The active substance in Tafamidis Accord, tafamidis, is a transthyretin stabiliser. It attaches to transthyretin, which prevents the protein from breaking up, thereby stopping the formation of amyloid in the heart and slowing down the progression of heart disease.
Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Vyndaqel, and do not need to be repeated for Tafamidis Accord.
As for every medicine, the company provided studies on the quality of Tafamidis Accord. The company also carried out a study that showed that it is ‘bioequivalent’ to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.
Studies carried out with Tafamidis Accord are described in more detail in the medicine’s assessment reports.
Because Tafamidis Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.
The European Medicines Agency concluded that, in accordance with EU requirements, Tafamidis Accord has been shown to have comparable quality and to be bioequivalent to the reference medicine. Therefore, the Agency’s view was that, as for Vyndaqel, the benefits of Tafamidis Accord outweigh the identified risks and it can be authorised for use in the EU.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tafamidis Accord have been included in the summary of product characteristics and the package leaflet. Any additional measures in place for Vyndaqel also apply to Tafamidis Accord where appropriate.
The company that markets Tafamidis Accord will provide educational material to all healthcare professionals expected to prescribe Tafamidis Accord. The material will include information about the need to use contraception (birth control) and avoid pregnancy while using the medicine. It also explains how to take part in a surveillance programme for pregnant women.
These materials may be made available by national competent authorities on their websites. A list of national repositories is available on this website.
As for all medicines, data on the use of Tafamidis Accord are continuously monitored. Suspected side effects reported with Tafamidis Accord are carefully evaluated and any necessary action taken to protect patients.
Tafamidis Accord received a marketing authorisation valid throughout the EU on 18 September 2026.
For information about the availability of this medicine in your country, contact your national competent authority.
Product information
18/09/2026
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Tafamidis Accord
- Active substance
- tafamidis
- International non-proprietary name (INN) or common name
- tafamidis
- Therapeutic area (MeSH)
- Amyloidosis, Familial
- Cardiomyopathies
- Anatomical therapeutic chemical (ATC) code
- N07XX08
Pharmacotherapeutic group
Other nervous system drugsTherapeutic indication
Tafamidis Accord is indicated for the treatment of hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTRh-CM).
News on Tafamidis Accord
This page was last updated on